NSF $500,000 phase IIb funding follows success from STTR phase I and II projects.

Fundamental Applied Biology (FAB) received $500,000 for the development of its cell-free protein synthesis technology toward commercialization. This SBIR phase IIB grant comes from the NSF.

During the STTR phase I and phase II NSF projects, FAB reported that certain proteins could be made in a soluble form through a cell-free system that was controllable and efficient. With the current award, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB’s first target product.

“The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity,” says Daniel S. Gold, Ph.D., CEO.

Previous articleAkrimax Purchases Wyeth’s Rouses Point Facility
Next articleInternational Consortium Takes On Malaria Vaccine Development with $23.6M over Four Years